Three analysts set AUD 4.37 target for 4Dmedical stock

Published on 10/17/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY26 revenue was AUD 7.10 million, up 21.00 percent. 4Dmedical stock was AUD 4.09 on October 16, 2026, up 0.25 percent from AUD 4.08.

Analyst valuation and company dates

Three analysts supported an AUD 4.37 consensus target on October 13, 2026.
Fiscal 2026 operating revenue reached AUD 7.10 million, up 21.00 percent from fiscal 2025.
4Dmedical stock was AUD 4.09 on October 16, 2026, up 0.25 percent from AUD 4.08.
4Dmedical scheduled its annual general meeting for October 28, 2026.

4Dmedical, AU0000095416, Illustration mit AI erstellt.

Three analysts set an AUD 4.37 consensus target for 4Dmedical, leaving the target 6.85 percent above the latest AUD 4.09 price. StockAnalysis reported the target and analyst count on October 13, 2026. 4Dmedical stock was last at AUD 4.09 on October 16, 2026 at 4:19 p.m. AEST, up 0.25 percent from the previous close of AUD 4.08.

Revenue growth sets the operating base

Fiscal 2026 operating revenue reached AUD 7.10 million, up 21.00 percent from fiscal 2025. The annual report also listed a gross margin of 93.00 percent, 540 installed sites and 344,075 scans for the year ended June 30, 2026. FinancialFilings carried those figures from the fiscal 2026 annual report.

Price position after the latest session

The latest AUD 4.09 price stood within a 52-week range of AUD 1.40 to AUD 7.55. It was 45.83 percent below the 52-week high, while the stock price had gained 122.28 percent over the same 52-week period. Average 20-day volume was 3,615,642 shares, compared with 3,058,146 shares in the October 16 session.

Valuation and the next date

The company had a market capitalization of AUD 2.5 billion as of October 16, 2026. The latest consensus target of AUD 4.37 was paired with a Hold rating and three analysts, according to StockAnalysis. 4Dmedical's annual general meeting is scheduled for October 28, 2026, according to an ASX filing published through Listcorp on October 15, 2026.

Comparison with peers

4Dmedical (ASX, AUD): plus 0.25 percent, market capitalization AUD 2.5 billion

Pro Medicus (ASX, AUD): plus 7.43 percent, P/E 69.19, market capitalization AUD 18.4 billion

ResMed (ASX, AUD): plus 2.26 percent, P/E 22.98, market capitalization AUD 48.3 billion

What the target means for valuation

The AUD 4.37 consensus target sits above the latest AUD 4.09 price, but the comparison with larger Australian medical technology companies shows a wide difference in market value. The next concrete date is the October 28, 2026 annual general meeting.

4Dmedical stock market snapshot

4Dmedical Limited operates in medical devices and develops software for lung and cardiopulmonary imaging. Its fiscal 2026 operating revenue grew 21.00 percent, while the stock price remained 45.83 percent below its 52-week high.